Clinical Trial Update: Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating Anti-GD2 CAR T cells in pediatric patients with high-risk or relapsed/refractory neuroblastoma and other GD2-positive solid …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ewing Sarcoma
• Neuroblastoma
• Osteosarcoma
• Sarcoma

Drugs mentioned

• Anti-GD2 CAR T Cells

Snippet

Sponsor: Bambino Gesù Hospital and Research Institute | Conditions: Neuroblastoma, Neuroblastoma Recurrent | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING